Literature DB >> 9066021

An alternative method for PAI-1 promoter polymorphism (4G/5G) typing.

M Margaglione, E Grandone, G Cappucci, D Colaizzo, N Giuliani, G Vecchione, M d'Addedda, G Di Minno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9066021

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  14 in total

1.  Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Authors:  Mark D Sternlicht; Alison M Dunning; Dan H Moore; Paul D P Pharoah; David G Ginzinger; Koei Chin; Joe W Gray; Frederic M Waldman; Bruce A J Ponder; Zena Werb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

2.  No evidence for plasminogen activator inhibitor 1 4G/4G genotype as risk factor for cerebral venous thrombosis.

Authors:  Christoph Lichy; Manja Kloss; Peter Reismann; Just Genius; Armin Grau; Karl Reuner
Journal:  J Neurol       Date:  2007-06-26       Impact factor: 4.849

3.  PAI-1 mRNA expression and plasma level in rheumatoid arthritis: relationship with 4G/5G PAI-1 polymorphism.

Authors:  José Francisco Muñoz-Valle; Sandra Luz Ruiz-Quezada; Edith Oregón-Romero; Rosa Elena Navarro-Hernández; Eduardo Castañeda-Saucedo; Ulises De la Cruz-Mosso; Berenice Illades-Aguiar; Marco Antonio Leyva-Vázquez; Natividad Castro-Alarcón; Isela Parra-Rojas
Journal:  Rheumatol Int       Date:  2011-12-27       Impact factor: 2.631

4.  An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients.

Authors:  Catherine F Li; Robert Y Wei; Frank Baliko; Bharati Bapat; Benjamin A Alman
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

5.  Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation.

Authors:  Dmitry A Zateyshchikov; Alexey N Brovkin; Dimitry A Chistiakov; Valery V Nosikov
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

6.  A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia.

Authors:  Kevin K Kim; Kevin R Flaherty; Qi Long; Noboru Hattori; Thomas H Sisson; Thomas V Colby; William D Travis; Fernando J Martinez; Susan Murray; Richard H Simon
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

7.  Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent.

Authors:  Gloria García-Segarra; Gerard Espinosa; Dolors Tassies; Josep Oriola; Jesús Aibar; Albert Bové; Pedro Castro; Joan-Carles Reverter; Josep-Maria Nicolás
Journal:  Intensive Care Med       Date:  2007-05-31       Impact factor: 41.787

8.  Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.

Authors:  Kristine Marie Jessen; Sarah Bjerre Lindboe; Anncatrine Luisa Petersen; Jesper Eugen-Olsen; Thomas Benfield
Journal:  BMC Infect Dis       Date:  2007-09-18       Impact factor: 3.090

9.  Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma.

Authors:  Georg Mossböck; Martin Weger; Christoph Faschinger; Otto Schmut; Wilfried Renner
Journal:  Mol Vis       Date:  2008-07-04       Impact factor: 2.367

10.  The role of TPA I/D and PAI-1 4G/5G polymorphisms in multiple sclerosis.

Authors:  Maja Zivković; Nada Starčević Čizmarević; Luca Lovrečić; Inge Klupka-Sarić; Aleksandra Stanković; Iva Gašparović; Polona Lavtar; Evica Dinčić; Ljiljana Stojković; Gorazd Rudolf; Saša Sega Jazbec; Olivio Perković; Osman Sinanović; Juraj Sepčić; Miljenko Kapović; Borut Peterlin; Smiljana Ristić
Journal:  Dis Markers       Date:  2014-04-16       Impact factor: 3.434
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.